New Diagnostic Predicts Breast Cancer Relapse Before Tumors Reappear
This article was originally published in Clinica
Executive Summary
A new study shows that noninvasive mutation-tracking in plasma DNA can detect minimal residual disease (MRD) in breast cancer patients following treatment and identify patients at high risk of recurrence.